Skip to content

BAXTER

Active
Public limited companyfounded 196858 yrs activeBoulevard René Branquart(L) 80, 7860 Lessines, BelgiumKBO/BCE: BE 0403.093.693
Summary

BAXTER has been active since 1968 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €83.8m and a net result of €6.2m. Equity is growing by ~10.2% per year across the filed fiscal years. Its solvency ranks better than 58% of 68 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).

Risk analysis Watch Report Compare
BAXTERActiveChecked score 78/100
Risk analysis Report Compare

Checked score

Score 2025
78 / 100
Excellent
Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability75▼-7
Solvency77▲+2
Growth51▼-17
Track record100
Bankruptcy probability, 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €2,000,000 at 30 days acceptable
Liquidity tight (current ratio 1.44 against 2.84 in 2024; short-term debt: 38.7% of total assets), and 47.6% of the assets are financed with debt.
Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 58 years 0 60 y
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
52.4%
Return on assets
3.8%
Age of the figures
9 mo
raises risk · Multiple establishment units
Several establishment units mean more fixed costs, and such companies fail more often than a company with one establishment.
KBO · establishment units
lowers risk · Lower-risk legal form
Companies with this legal form statistically fail less often than a BV.
KBO · legal form
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)
about 14% more bankruptcies
← fewer bankruptcies more bankruptcies →
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 08-07-2026, 23 days ahead of the deadline.
NBB · 5 filings
Deviation from the deadline
2025
23 d early
2024
22 d early
2023
22 d early
2022
21 d early
2021
19 d early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 5 accounts on average 21 days before the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 10 July (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Position in the running window
29-09-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

BAXTER was incorporated on 1 January 1968.1 The board currently has 5 members; Frédéric Yannart has served longest, since 2021.2 Revenue grew from EUR 80 million in 2018 to EUR 107 million in 2025 and headcount from 834 to 901 full-time equivalents.3

  1. 1Crossroads Bank for Enterprises
  2. 2Belgian State Gazette, 12-05-2021
  3. 3National Bank, annual accounts 2018 and 2025

Go further with this company

How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Is the workforce growing, and do people stay?Employer check Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2025, full schema, statutory accounts

In the rankings #2 company by total assets in Hainaut, Pharmaceuticals sector#2 company by equity in Hainaut, Pharmaceuticals sector#2 employer in Lessines
Turnover
€106.6m▲ 2.2%
2024 · €104.2m
EBIT margin
7.7%▼ 0.2pp
2024 · 7.9%
Net result
€6.2m▼ 64.0%
2024 · €17.1m
Working capital
€26.9m▼ 51.2%
2024 · €55.2m
Trend over the years

Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations, each year against the same schema; no band under 30 filings. Dashed line: the median.

Every figure with its change against the fiscal year before
favourable unfavourable
Line20212022202320242025
Turnover€99.8m▲ 7.8%€102.0m▲ 2.1%€106.3m▲ 4.3%€104.2m▼ 2.0%€106.6m▲ 2.2%
Operating result€7.2m▲ 13.7%€10.5m▲ 46.6%€8.6m▼ 18.3%€8.2m▼ 4.5%€8.2m▼ 0.1%
Net result€4.8mabove the sector's middle half▲ 3.4%€12.4mabove the sector's middle half▲ 160%€6.5mabove the sector's middle half▼ 47.9%€17.1mabove the sector's middle half▲ 163%€6.2mabove the sector's middle half▼ 64.0%
EBIT margin7.2%▲ 0.4pp10.3%▲ 3.1pp8.1%▼ 2.2pp7.9%▼ 0.2pp7.7%▼ 0.2pp
Equity€54.9mabove the sector's middle half▲ 8.8%€67.0mabove the sector's middle half▲ 21.9%€73.1mabove the sector's middle half▲ 9.2%€77.9mabove the sector's middle half▲ 6.6%€83.8mabove the sector's middle half▲ 7.6%
Total assets€132.0mabove the sector's middle half▼ 1.6%€141.3mabove the sector's middle half▲ 7.1%€150.8mabove the sector's middle half▲ 6.8%€154.8mabove the sector's middle half▲ 2.6%€160.0mabove the sector's middle half▲ 3.4%
Debt€76.3m▼ 7.9%€72.9m▼ 4.5%€76.2m▲ 4.5%€75.5m▼ 0.9%€75.2m▼ 0.4%
Working capital€27.5mabove the sector's middle half€39.6mabove the sector's middle half▲ 44.2%€47.6mabove the sector's middle half▲ 20.1%€55.2mabove the sector's middle half▲ 15.9%€26.9mabove the sector's middle half▼ 51.2%
Solvency41.6%within the sector's middle half▲ 4.0pp47.4%within the sector's middle half▲ 5.8pp48.5%within the sector's middle half▲ 1.1pp50.3%within the sector's middle half▲ 1.9pp52.4%within the sector's middle half▲ 2.0pp
Current ratio1.96within the sector's middle half▲ 1.072.54within the sector's middle half▲ 0.582.63within the sector's middle half▲ 0.092.84above the sector's middle half▲ 0.221.44within the sector's middle half▼ 1.41
Return on assets (ROA)3.6%within the sector's middle half▲ 0.2pp8.8%above the sector's middle half▲ 5.2pp4.3%within the sector's middle half▼ 4.5pp11.0%above the sector's middle half▲ 6.7pp3.8%within the sector's middle half▼ 7.2pp
Staff (FTE)925.4above the sector's middle half▲ 8.1%915.2above the sector's middle half▼ 1.1%932.3above the sector's middle half▲ 1.9%900.4above the sector's middle half▼ 3.4%901.3above the sector's middle half▲ 0.1%
above within below the middle half (P25 to P75) of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations, each year against the same schema; no band under 30 filings.
Result per fiscal year
Operating resultNet result
€0€5.0m€10.0m€15.0mOperating result 2021: €7.2m€7.2mNet result 2021: €4.8m€4.8mOperating result 2022: €10.5m€10.5mNet result 2022: €12.4m€12.4mOperating result 2023: €8.6m€8.6mNet result 2023: €6.5m€6.5mOperating result 2024: €8.2m€8.2mNet result 2024: €17.1m€17.1mOperating result 2025: €8.2m€8.2mNet result 2025: €6.2m€6.2m20212022202320242025€0€5m€10m€15mOperating result 2023: €8.6m€8.6mNet result 2023: €6.5m€6.5mOperating result 2024: €8.2m€8.2mNet result 2024: €17.1m€17mOperating result 2025: €8.2m€8.2mNet result 2025: €6.2m€6.2m202320242025
The operating result has fallen three years in a row; 2025 is 0% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €160.0m
Fixed assets €71.1m ▲ 2.1%
Current assets €88.9m ▲ 4.4%
Equity and liabilities €160.0m
Equity €83.8m ▲ 7.6%
Provisions €962,157 ▼ 28.2%
Debt €75.2m ▼ 0.4%
Debt's share of the balance-sheet total falls from 48.8% to 47.0%. Equity is higher and debt is lower.
Key figures and ratios
2025 value · change against 2024
EBITDA
€15.0m▼
2024 · €15.5m
Cash flow
€13.0m▼
2024 · €24.3m
Quick ratio
1.28▼
2024 · 2.54
Debt to equity
0.90▼
2024 · 0.97
ROE
7.3%▼
2024 · 21.9%
Interest coverage
8.70▲
2024 · 7.12
Debt ≤ 1 year
€61.9m▲
2024 · €29.9m
Debt > 1 year
€13.3m▼
2024 · €45.6m
Income taxes
€1.2m▲
2024 · €651,739
Staff costs
€71.0m▲
2024 · €69.6m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 491 companies that looked in July 2024 the way this one looks now, 0.8% went bankrupt within 24 months and 96% are still going.

  • Large
  • 20 years or older
  • solvency 30% or more
  • a profit under 5% of the balance sheet
0.8% went bankrupt
3.3% stopped otherwise
96% still going

For this company itself Checked computes a bankruptcy probability of 0.3% over twelve months; the group does not contradict it.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,338 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.9%
9 3.0% 3.1%
10 5.6% 6.2%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 491 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 90 lines
Balance sheet Code20242025
Assets
Total assets20/58€154.8m€160.0m▲
Fixed assets21/28€69.7m€71.1m▲
Intangible fixed assets21€1.1m€780,501▼
Tangible fixed assets22/27€47.8m€49.5m▲
Land and buildings22€9.7m€9.7m=
Plant, machinery and equipment23€18.1m€17.5m▼
Furniture and vehicles24€210,799€148,402▼
Leasing and similar rights25€15.2m€14.7m▼
Assets under construction and advance payments27€4.5m€7.5m▲
Financial fixed assets28€20.8m€20.8m=
Affiliated companies280/1€20.8m€20.8m=
Participating interests280€20.8m€20.8m=
Current assets29/58€85.1m€88.9m▲
Stocks and contracts in progress3€9.2m€9.9m▲
Stocks30/36€9.2m€9.9m▲
Raw materials and consumables30/31€9.2m€9.9m▲
Finished goods33€0€0=
Amounts receivable within one year40/41€41.0m€38.8m▼
Trade receivables40€37.9m€36.4m▼
Other amounts receivable41€3.0m€2.5m▼
Current investments50/53€34.7m€40.0m▲
Other investments51/53€34.7m€40.0m▲
Deferred charges and accrued income490/1€206,088€127,372▼
Equity and liabilities
Total equity and liabilities10/49€154.8m€160.0m▲
Equity10/15€77.9m€83.8m▲
Contributions10/11€7.1m€7.1m=
Capital10€7.1m€7.1m=
Issued capital100€7.1m€7.1m=
Reserves13€2.2m€2.2m=
Non-distributable reserves130/1€732,432€732,432=
Legal reserve130€712,242€712,242=
Other1319€20,190€20,190=
Tax-exempt reserves132€1.5m€1.5m=
Profit (loss) carried forward14€67.9m€74.0m▲
Investment grants15€741,059€473,084▼
Provisions and deferred taxes16€1.3m€962,157▼
Provisions for liabilities and charges160/5€1.3m€948,913▼
Other liabilities and charges164/5€1.3m€948,913▼
Deferred taxes168€14,346€13,244▼
Amounts payable17/49€75.5m€75.2m▼
Amounts payable after more than one year17€45.6m€13.3m▼
Financial debts170/4€45.6m€13.3m▼
Leasing and similar obligations172€14.4m€13.3m▼
Other loans174€31.2m€0▼
Amounts payable within one year42/48€29.9m€61.9m▲
Current portion of amounts payable after more than one year42€2.8m€2.8m▼
Financial debts43€0€31.2m▲
Credit institutions430/8€0€0=
Other loans439€0€31.2m▲
Trade debts44€16.9m€17.8m▲
Suppliers440/4€16.9m€17.8m▲
Taxes, remuneration and social security45€10.2m€10.2m▼
Taxes450/3€444,241€0▼
Remuneration and social security454/9€9.8m€10.2m▲
Accrued charges and deferred income492/3€12€87▲
Income statement Code20242025
Operating income70/76A€117.7m€120.0m▲
Turnover70€104.2m€106.6m▲
Own construction capitalised72€857,758€1.1m▲
Other operating income74€12.7m€12.3m▼
Operating charges60/66A€109.5m€111.8m▲
Goods for resale, raw materials and consumables60€1.9m€1.5m▼
Purchases600/8€3.3m€2.2m▼
Change in stocks: decrease (increase)609-€1.5m-€660,124▲
Services and other goods61€27.0m€28.4m▲
Remuneration, social security and pensions62€69.6m€71.0m▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€7.2m€6.8m▼
Provisions for liabilities and charges: additions (uses and reversals)635/8-€194,042-€376,283▼
Other operating charges640/8€3.9m€4.3m▲
Non-recurring operating charges66A€0€11,104▲
Operating profit (loss)9901€8.2m€8.2m▼
Financial income75/76B€11.9m€995,935▼
Recurring financial income75€1.6m€995,935▼
Income from current assets751€1.1m€519,112▼
Other financial income752/9€464,858€476,823▲
Non-recurring financial income76B€10.4m€0▼
Financial charges65/66B€2.4m€1.9m▼
Recurring financial charges65€2.4m€1.9m▼
Debt charges650€2.2m€1.7m▼
Other financial charges652/9€238,343€142,134▼
Profit (loss) for the period before taxes9903€17.7m€7.3m▼
Transfer from deferred taxes780€1,900€1,102▼
Income taxes67/77€651,739€1.2m▲
Taxes670/3€651,739€1.2m▲
Profit (loss) for the period9904€17.1m€6.2m▼
Profit (loss) for the period to be appropriated9905€17.1m€6.2m▼
Appropriation of the result
Profit (loss) to be appropriated9906€79.9m€74.0m▼
Profit (loss) brought forward from the previous period14P€62.8m€67.9m▲
Profit to be distributed694/7€12.0m€0▼
Return on contributions (dividend)694€12.0m€0▼
Social balance
Average headcount (FTE)9087900.4901.3▲

The notes to these accounts (96 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line20212022202320242025Change
Operating income70/76A€111.7m€115.6m€121.1m€117.7m€120.0m▲ 1.9%
Turnover70€99.8m€102.0m€106.3m€104.2m€106.6m▲ 2.2%
Own construction capitalised72€772,869€889,573€828,887€857,758€1.1m▲ 30.8%
Other operating income74€11.1m€12.7m€13.9m€12.7m€12.3m▼ 2.7%
Operating charges60/66A€104.5m€105.0m€112.4m€109.5m€111.8m▲ 2.1%
Goods for resale, raw materials and consumables60€6.1m€4.3m€2.8m€1.9m€1.5m▼ 18.6%
Purchases600/8€6.4m€4.7m€2.9m€3.3m€2.2m▼ 34.3%
Change in stocks: decrease (increase)609-€368,864-€365,521-€104,804-€1.5m-€660,124▲ 54.5%
Services and other goods61€21.9m€23.3m€25.0m€27.0m€28.4m▲ 5.2%
Remuneration, social security and pensions62€63.9m€66.3m€73.5m€69.6m€71.0m▲ 2.0%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€8.5m€6.8m€7.3m€7.2m€6.8m▼ 5.9%
Provisions for liabilities and charges: additions (uses and reversals)635/8€19,931€705,222€78,670-€194,042-€376,283▼ 93.9%
Other operating charges640/8€4.0m€3.3m€3.7m€3.9m€4.3m▲ 11.3%
Non-recurring operating charges66A€98,575€392,448€0€0€11,104-
Operating profit (loss)9901€7.2m€10.5m€8.6m€8.2m€8.2m▼ 0.1%
Financial income75/76B€405,588€2.8m€1.4m€11.9m€995,935▼ 91.6%
Recurring financial income75€405,588€564,073€1.4m€1.6m€995,935▼ 36.1%
Income from financial fixed assets750€0-----
Income from current assets751-€52,421€786,274€1.1m€519,112▼ 52.5%
Other financial income752/9€405,588€511,652€580,553€464,858€476,823▲ 2.6%
Non-recurring financial income76B-€2.2m€0€10.4m€0▼ 100%
Financial charges65/66B€503,280€856,639€2.1m€2.4m€1.9m▼ 22.3%
Recurring financial charges65€503,280€856,639€2.1m€2.4m€1.9m▼ 22.3%
Debt charges650€320,357€649,161€1.8m€2.2m€1.7m▼ 20.4%
Other financial charges652/9€182,923€207,478€272,231€238,343€142,134▼ 40.4%
Profit (loss) for the period before taxes9903€7.1m€12.5m€7.9m€17.7m€7.3m▼ 58.6%
Transfer from deferred taxes780€27,383€2,151€1,899€1,900€1,102▼ 42.0%
Income taxes67/77€2.3m€13,937€1.4m€651,739€1.2m▲ 83.9%
Taxes670/3€2.3m€13,937€1.4m€651,739€1.2m▲ 83.9%
Profit (loss) for the period9904€4.8m€12.4m€6.5m€17.1m€6.2m▼ 64.0%
Profit (loss) for the period to be appropriated9905€4.8m€12.4m€6.5m€17.1m€6.2m▼ 64.0%
Line20212022202320242025Change
Assets
Total assets20/58€132.0m€141.3m€150.8m€154.8m€160.0m▲ 3.4%
Fixed assets21/28€75.7m€75.9m€74.0m€69.7m€71.1m▲ 2.1%
Intangible fixed assets21€1.3m€1.4m€1.2m€1.1m€780,501▼ 27.3%
Tangible fixed assets22/27€52.0m€52.0m€50.3m€47.8m€49.5m▲ 3.7%
Land and buildings22€10.3m€9.7m€10.0m€9.7m€9.7m=
Plant, machinery and equipment23€27.2m€19.6m€20.2m€18.1m€17.5m▼ 3.4%
Furniture and vehicles24€189,506€193,687€252,502€210,799€148,402▼ 29.6%
Leasing and similar rights25€9.0m€15.4m€15.9m€15.2m€14.7m▼ 3.4%
Assets under construction and advance payments27€5.3m€7.1m€4.0m€4.5m€7.5m▲ 64.9%
Financial fixed assets28€22.5m€22.5m€22.5m€20.8m€20.8m=
Affiliated companies280/1€22.5m€22.5m€22.5m€20.8m€20.8m=
Participating interests280€22.5m€22.5m€22.5m€20.8m€20.8m=
Current assets29/58€56.3m€65.4m€76.9m€85.1m€88.9m▲ 4.4%
Stocks and contracts in progress3€7.3m€7.7m€7.8m€9.2m€9.9m▲ 7.2%
Stocks30/36€7.3m€7.7m€7.8m€9.2m€9.9m▲ 7.2%
Raw materials and consumables30/31€7.3m€7.7m€7.8m€9.2m€9.9m▲ 7.2%
Finished goods33€75€75€75€0€0-
Amounts receivable within one year40/41€42.9m€36.6m€31.8m€41.0m€38.8m▼ 5.3%
Trade receivables40€40.7m€31.4m€28.5m€37.9m€36.4m▼ 4.2%
Other amounts receivable41€2.2m€5.2m€3.3m€3.0m€2.5m▼ 19.3%
Current investments50/53€6.0m€21.0m€36.8m€34.7m€40.0m▲ 15.4%
Other investments51/53€6.0m€21.0m€36.8m€34.7m€40.0m▲ 15.4%
Deferred charges and accrued income490/1€47,342€124,733€491,497€206,088€127,372▼ 38.2%
Equity and liabilities
Total equity and liabilities10/49€132.0m€141.3m€150.8m€154.8m€160.0m▲ 3.4%
Equity10/15€54.9m€67.0m€73.1m€77.9m€83.8m▲ 7.6%
Contributions10/11€7.1m€7.1m€7.1m€7.1m€7.1m=
Capital10€7.1m€7.1m€7.1m€7.1m€7.1m=
Issued capital100€7.1m€7.1m€7.1m€7.1m€7.1m=
Reserves13€2.2m€2.2m€2.2m€2.2m€2.2m=
Non-distributable reserves130/1€732,432€732,432€732,432€732,432€732,432=
Legal reserve130€712,242€712,242€712,242€712,242€712,242=
Other1319€20,190€20,190€20,190€20,190€20,190=
Tax-exempt reserves132€1.5m€1.5m€1.5m€1.5m€1.5m=
Profit (loss) carried forward14€43.8m€56.3m€62.8m€67.9m€74.0m▲ 9.1%
Investment grants15€1.8m€1.4m€1.0m€741,059€473,084▼ 36.2%
Provisions and deferred taxes16€755,642€1.5m€1.5m€1.3m€962,157▼ 28.2%
Provisions for liabilities and charges160/5€735,346€1.4m€1.5m€1.3m€948,913▼ 28.4%
Other liabilities and charges164/5€735,346€1.4m€1.5m€1.3m€948,913▼ 28.4%
Deferred taxes168€20,296€18,145€16,246€14,346€13,244▼ 7.7%
Amounts payable17/49€76.3m€72.9m€76.2m€75.5m€75.2m▼ 0.4%
Amounts payable after more than one year17€47.5m€47.0m€46.9m€45.6m€13.3m▼ 70.8%
Financial debts170/4€47.5m€47.0m€46.9m€45.6m€13.3m▼ 70.8%
Leasing and similar obligations172€16.5m€15.8m€15.6m€14.4m€13.3m▼ 7.3%
Other loans174€31.0m€31.2m€31.3m€31.2m€0▼ 100%
Amounts payable within one year42/48€28.8m€25.7m€29.3m€29.9m€61.9m▲ 107%
Current portion of amounts payable after more than one year42€2.4m€2.5m€2.7m€2.8m€2.8m▼ 0.8%
Financial debts43€0€0€0€0€31.2m-
Credit institutions430/8€0€0€0€0€0-
Other loans439€0€0€0€0€31.2m-
Trade debts44€12.5m€11.3m€13.6m€16.9m€17.8m▲ 4.9%
Suppliers440/4€12.5m€11.3m€13.6m€16.9m€17.8m▲ 4.9%
Taxes, remuneration and social security45€13.9m€12.0m€13.0m€10.2m€10.2m▼ 0.5%
Taxes450/3€3.9m€1.2m€1.8m€444,241€0▼ 100%
Remuneration and social security454/9€10.0m€10.7m€11.2m€9.8m€10.2m▲ 4.1%
Accrued charges and deferred income492/3€3€150,003€69€12€87▲ 625%
Line20212022202320242025Change
Profit (loss) for the period9904€4.8m€12.4m€6.5m€17.1m€6.2m▼ 64.0%
+ Depreciation and write-downs630€8.5m€6.8m€7.3m€7.2m€6.8m▼ 5.9%
Operating cash flow (approximation)€13.3m€19.3m€13.8m€24.3m€13.0m▼ 46.7%
Investment in fixed assets (approximation)--€7.0m-€5.4m-€3.0m-€8.3m▼ 179%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

Next filing, fiscal year 2026, expected by 31-07-2027
2026
08-07
NBB filing Annual accounts filed
fiscal year 2025 · consolidated
08-07
NBB filing Annual accounts filed
fiscal year 2025 · full schema
2025
29-07
State Gazette act Reappointment: PwC Reviseurs d'Entreprises SRL (statutory auditor)
Permanent representative: Romain Seffer · Auditor representative4 facts ▸
  • General meeting, 30-06-2025
  • Auditor reappointment, PwC Reviseurs d'Entreprises SRL
  • Permanent representative, Romain Seffer
  • Auditor representative, Romain Seffer SRL
10-07
NBB filing Annual accounts filed
fiscal year 2024 · full schema
09-07
NBB filing Annual accounts filed
fiscal year 2024 · consolidated
22-05
State Gazette act Resignation: Lionel Rosoux (director and managing director)
Appointment: Abdellah El Kacem (director) · Mandate compensation9 facts ▸
  • General meeting, 28-03-2025
  • Director resignation, Lionel Rosoux (director and managing director)
  • Director appointment, Abdellah El Kacem (director)
  • Board composition, Frédéric Yannart (director)
  • Board composition, Guy In 't Ven (director)
  • Board composition, Serge Vandermotten (director)
  • Board composition, Abdellah El Kacem (director)
  • Board composition, Annelies Bryon (managing director)
  • Mandate compensation, BAXTER
2024
31-12
Financial Highest result since 2018net €17.1m ▲163%
Net result €17.1m, the highest in the series.
09-07
NBB filing Annual accounts filed
fiscal year 2023 · consolidated
09-07
NBB filing Annual accounts filed
fiscal year 2023 · full schema
08-07
State Gazette act Resignation: Herman Jacobs (director)
Mandate compensation8 facts ▸
  • General meeting, 24-05-2024
  • Director resignation, Herman Jacobs (director)
  • Board composition, Frédéric Yannart (director)
  • Board composition, Guy In 't Ven (director)
  • Board composition, Serge Vandermotten (director)
  • Board composition, Annelies Bryon (managing director)
  • Board composition, Lionel Rosoux (managing director)
  • Mandate compensation, BAXTER
30-04
State Gazette act Resignation: Adriano MARQUES ANTUNES (director)
Appointment: Lionel ROSOUX (director) · Mandate compensation13 facts ▸
  • General meeting, 01-03-2024
  • Director resignation, Adriano MARQUES ANTUNES (director)
  • Director appointment, Lionel ROSOUX (director)
  • Board composition, Herman Jacobs (director)
  • Board composition, Frédéric Yannart (director)
  • Board composition, Guy In 't Ven (director)
  • Board composition, Serge Vandermotten (director)
  • Board composition, Annelies Bryon (managing director)
  • Board composition, Lionel ROSOUX (managing director)
  • Mandate compensation, BAXTER
  • Board meeting, 01-03-2024
  • Director resignation, Adriano MARQUES ANTUNES (managing director)
  • +1 further facts in this act
20-03
State Gazette act Capital & shares
Statutes amendment1 fact ▸
  • Statutes amendment
Show earlier events
2023
28-07
State Gazette act Appointments: Adriano Marques Antunes (managing director) and Annelies Bryon (managing director)
3 facts ▸
  • Board meeting, 05-07-2023
  • Director appointment, Adriano Marques Antunes (managing director)
  • Director appointment, Annelies Bryon (managing director)
28-07
State Gazette act Resignation: Jacques Delbecq (director)
Appointments: Annelies Bryon, Guy In 't Ven and Serge Vandermotten · Mandate compensation12 facts ▸
  • General meeting, 26-06-2023
  • Director resignation, Jacques Delbecq (director)
  • Director appointment, Annelies Bryon (director)
  • Director appointment, Guy In 't Ven (director)
  • Director appointment, Serge Vandermotten (director)
  • Mandate compensation, BAXTER
  • Board composition, Herman Jacobs (director)
  • Board composition, Frédéric Yannart (director)
  • Board composition, Adriano Marques Antunes (director)
  • Board composition, Annelies Bryon (director)
  • Board composition, Guy In 't Ven (director)
  • Board composition, Serge Vandermotten (director)
25-07
NBB filing Annual accounts filed
fiscal year 2022 · consolidated
10-07
NBB filing Annual accounts filed
fiscal year 2022 · full schema
19-04
State Gazette act Reappointment: Herman Jacobs (director)
Mandate compensation8 facts ▸
  • General meeting, 15-03-2023
  • General meeting, 24-09-2020
  • Director reappointment, Herman Jacobs (director)
  • Board composition, Herman Jacobs (director)
  • Board composition, Frédéric Yannart (director)
  • Board composition, Jacques Delbecq (director)
  • Board composition, Adriano Marques Antunes (director)
  • Mandate compensation, BAXTER
2022
16-09
State Gazette act Reappointment: SRL PwC Reviseurs d'Entreprises (statutory auditor)
Permanent representative: Romain Seffer · Mandate term4 facts ▸
  • General meeting, 27-06-2022
  • Auditor reappointment, SRL PwC Reviseurs d'Entreprises (statutory auditor)
  • Permanent representative, Romain Seffer
  • Mandate term, à l'issue de l'assemblée générale des actionnaires appelée à statuer sur les comptes annuels de l'exercice social qui sera clôturé le 31 décembre 2024
14-07
NBB filing Annual accounts filed
fiscal year 2021 · consolidated
12-07
NBB filing Annual accounts filed
fiscal year 2021 · full schema
25-01
State Gazette act Resignation: Bhevan Chandrasena (director)
Mandate compensation7 facts ▸
  • General meeting, 06-01-2022
  • Director resignation, Bhevan Chandrasena (director)
  • Board composition, Herman Jacobs (director)
  • Board composition, Frédéric Yannart (director)
  • Board composition, Jacques Delbecg (director)
  • Board composition, Adriano Marques Antunes (director)
  • Mandate compensation, BAXTER
2021
31-12
Financial Liquidity doublescurrent ratio 1.96
Current ratio from 0.88 to 1.96; short-term debt falls from €66.9m to €28.8m.
22-12
State Gazette act Appointment: Adriano Marques Antunes (director)
Mandate compensation8 facts ▸
  • General meeting, 02-12-2021
  • Director appointment, Adriano Marques Antunes (director)
  • Board composition, Herman Jacobs (director)
  • Board composition, Bhevan Chandrasena (director)
  • Board composition, Frédéric Yannart (director)
  • Board composition, Jacques Delbecq (director)
  • Board composition, Adriano Marques Antunes (director)
  • Mandate compensation, BAXTER
24-08
State Gazette act Statutes amendment
Capital3 facts ▸
  • General meeting, 15-06-2021
  • Statutes amendment
  • Capital, €7.122.417
12-05
State Gazette act Resignation: Giuseppe Spatola (director)
Appointments: Frédéric Yannart (director) and Jacques Delbecq (director) · Mandate compensation9 facts ▸
  • General meeting, 15-03-2021
  • Director resignation, Giuseppe Spatola (director)
  • Director appointment, Frédéric Yannart (director)
  • Director appointment, Jacques Delbecq (director)
  • Board composition, Herman Jacobs (director)
  • Board composition, Bhevan Chandrasena (director)
  • Board composition, Frédéric Yannart (director)
  • Board composition, Jacques Delbecq (director)
  • Mandate compensation, BAXTER
03-02
State Gazette act Permanent representative: Romain Seffer
2 facts ▸
  • General meeting, 10-12-2020
  • Permanent representative, Romain Seffer
2020
31-12
Financial Weakest financial yearnet €4.6m ▼27.9%
Net result drops to €4.6m, the lowest in the series; recovery starts the following year.
31-12
Financial Equity above €50mEq €50.5m ▲8.9%
3 profitable years in a row build equity to €50.5m.
16-01
State Gazette act Resignation: Andrea Borrell Vila (director)
Mandate compensation6 facts ▸
  • General meeting, 29-10-2019
  • Director resignation, Andrea Borrell Vila (director)
  • Board composition, Herman Jacobs (director)
  • Board composition, Bhevan Chandrasena (director)
  • Board composition, Giuseppe Spatola (director)
  • Mandate compensation, BAXTER
2019
04-11
State Gazette act Appointment: Giuseppe Spatola (director)
Reappointment: Pricewaterhouse Coopers reviseurs d'entreprises (statutory auditor) · Mandate compensation8 facts ▸
  • General meeting, 24-06-2019
  • Director appointment, Giuseppe Spatola (director)
  • Board composition, Andrea Borrell Vila (director)
  • Board composition, Herman Jacobs (director)
  • Board composition, Bhevan Chandrasena (director)
  • Board composition, Giuseppe Spatola (director)
  • Mandate compensation, BAXTER
  • Auditor reappointment, Pricewaterhouse Coopers reviseurs d'entreprises
06-06
State Gazette act Statutes amendment
2 facts ▸
  • General meeting, 23-05-2019
  • Statutes amendment
2018
25-07
State Gazette act Resignation: Erich Kollegger (director)
Mandate compensation7 facts ▸
  • General meeting, 21-06-2018
  • Director resignation, Erich Kollegger (director)
  • Board composition, Andrea Borrell Vila (director)
  • Board composition, Herman Jacobs (director)
  • Board composition, Bhevan Chandrasena (director)
  • Mandate compensation, BAXTER
  • Board resolution, no replacement appointed for Erich Kollegger
2017
15-12
State Gazette act Permanent representative: Alexis VAN BAVEL
Statutory auditor2 facts ▸
  • Permanent representative, Alexis VAN BAVEL
  • Statutory auditor, PricewaterhouseCoopers Réviseurs d'Entreprises Scerl
2016
18-08
State Gazette act Reappointment: Pricewaterhouse Coopers reviseurs d'entreprises (statutory auditor)
2 facts ▸
  • General meeting, 16-06-2016
  • Auditor reappointment, Pricewaterhouse Coopers reviseurs d'entreprises
01-06
State Gazette act Resignation: Philippe Lodomez (director)
Appointment: Bhevan Chandrasena (director) · Mandate compensation8 facts ▸
  • General meeting, 15-03-2016
  • Director resignation, Philippe Lodomez (director)
  • Director appointment, Bhevan Chandrasena (director)
  • Board composition, Andrea Borrell Vila (director)
  • Board composition, Herman Jacobs (director)
  • Board composition, Erich Kollegger (director)
  • Board composition, Bhevan Chandrasena (director)
  • Mandate compensation, BAXTER
2015
09-07
State Gazette act Resignation: Emmanuel Felix (director)
6 facts ▸
  • General meeting, 04-06-2015
  • Director resignation, Emmanuel Felix (director)
  • Board composition, Philippe Lodomez (director)
  • Board composition, Andrea Borrell Vila (director)
  • Board composition, Herman Jacobs (director)
  • Board composition, Erich Kollegger (director)
06-07
State Gazette act Capital & shares · Restructuring
Demerger · Accounting effect · Share issue11 facts ▸
  • General meeting, 30-04-2015
  • Demerger, Activité Baxalta
  • Accounting effect, 01-01-2015
  • Share issue, nominatives, entièrement libérées et sans valeur nominale, 6428558
  • Capital decrease, €15.614.853
  • Capital, €7.122.417
  • Statutes amendment
  • Suspensive condition, décision concordante de scission partielle et d'augmentation de capital par l'assemblée générale extraordinaire des actionnaires de la société scindée
  • No cash consideration, Aucune soulte ne sera versée.
  • No share exchange, les actions existantes dans la société transférante ne seront pas échangées pour des actions dans la société scindée
  • Mixed assets, les actifs mixtes ne seront pas transférés à la société scindée et demeureront au sein de la société transférante (sans préjudice aux contrats mixtes, dont la p…
12-03
State Gazette act Restructuring
Demerger · Capital increase · Capital decrease18 facts ▸
  • Demerger, Transfert des Activités Baxalta de la Société Transférante à la Société Scindée
  • Capital increase, €15.614.853
  • Capital decrease, €15.614.853
  • Share issue, Nouvelles Actions, 6428558
  • Net-asset statement, 31-12-2014
  • Accounting effect, 01-01-2015
  • Proposal date, 27-02-2015
  • Expected approval date, 30-04-2015
  • Shareholding, 10415, 99,9712%
  • Shareholding, 6149, 99,9837%
  • Shareholding, 3, 0,0288%
  • Shareholding, 1, 0,0163%
  • +6 further facts in this act
04-03
State Gazette act Reappointments: Andrea Borrell Vila, Philippe Lodomez and 3 others
11 facts ▸
  • General meeting, 30-06-2014
  • Director reappointment, Andrea Borrell Vila (director)
  • Director reappointment, Philippe Lodomez (director)
  • Director reappointment, Hermann Jacobs (director)
  • Director reappointment, Emmanuel Félix (director)
  • Director reappointment, Erich Kollegger (director)
  • Board composition, Philippe Lodomez (director)
  • Board composition, Andrea Borrell Vila (director)
  • Board composition, Hermann Jacobs (director)
  • Board composition, Emmanuel Félix (director)
  • Board composition, Erich Kollegger (director)
2014
18-03
State Gazette act Resignation: Achille Ghillotti (director)
Appointment: Erich Kollegger (director)8 facts ▸
  • General meeting, 15-01-2014
  • Director resignation, Achille Ghillotti (director)
  • Director appointment, Erich Kollegger (director)
  • Board composition, Philippe Lodomez (director)
  • Board composition, Andrea Borrell Vila (director)
  • Board composition, Hermann Jacobs (director)
  • Board composition, Emmanuel Felix (director)
  • Board composition, Erich Kollegger (director)
2013
27-08
State Gazette act Resignation: Mario Ricard (director)
Appointments: Herman Jacobs (director) and Emmanuel Félix (director) · Reappointment: PricewaterhouseCoopers reviseurs d'Entreprises (statutory auditor)10 facts ▸
  • General meeting, 20-06-2013
  • Director resignation, Mario Ricard (director)
  • Director appointment, Herman Jacobs (director)
  • Director appointment, Emmanuel Félix (director)
  • Board composition, Philippe Lodomez (director)
  • Board composition, Andrea Borrell Vila (director)
  • Board composition, Achille Ghilotti (director)
  • Board composition, Herman Jacobs (director)
  • Board composition, Emmanuel Félix (director)
  • Auditor reappointment, PricewaterhouseCoopers reviseurs d'Entreprises
30-01
State Gazette act Capital & shares
Branch creation2 facts ▸
  • Board meeting, 21-12-2012
  • Branch creation, Création d'une unité d'établissement
2012
04-12
State Gazette act Resignations: Michael Costello (director) and Emmanuel Foy (director)
Appointment: Achille Ghilotti (director) · Mandate term · Mandate compensation10 facts ▸
  • General meeting, 01-10-2012
  • Director resignation, Michael Costello (director)
  • Director resignation, Emmanuel Foy (director)
  • Director appointment, Achille Ghilotti (director)
  • Mandate term, jusqu'à l'assemblée générale ordinaire des actionnaires à tenir en 2014 qui délibèrera sur les comptes annuels clôturés au 31 décembre 2013
  • Board composition, Philippe Lodomez (director)
  • Board composition, Mario Ricard (director)
  • Board composition, Andrea Borrell Vila (director)
  • Board composition, Achille Ghilotti (director)
  • Mandate compensation, BAXTER
18-09
State Gazette act Resignation: Anja Verbeke (director)
Appointment: Andrea Borrell Vila (director) · Mandate compensation9 facts ▸
  • General meeting, 21/06/2012
  • Director resignation, Anja Verbeke (director)
  • Director appointment, Andrea Borrell Vila (director)
  • Board composition, Emmanuel Foy (director)
  • Board composition, Philippe Lodomez (director)
  • Board composition, Mario Ricard (director)
  • Board composition, Michael Costello (director)
  • Board composition, Andrea Borrell Vila (director)
  • Mandate compensation, BAXTER
03-01
State Gazette act Permanent representatives: Alexis Van Bavel and Emeric Seeuws
Resignation: Raynald Vermoesen (permanent representative)4 facts ▸
  • General meeting, 09-12-2011
  • Permanent representative, Alexis Van Bavel
  • Permanent representative, Emeric Seeuws
  • Director resignation, Raynald Vermoesen (permanent representative)
2011
17-11
State Gazette act Appointment: Michael Costello (director)
7 facts ▸
  • General meeting, 10-10-2011
  • Director appointment, Michael Costello (director)
  • Board composition, Anja Verbeke (director)
  • Board composition, Emmanuel Foy (director)
  • Board composition, Philippe Lodomez (director)
  • Board composition, Mario Ricard (director)
  • Board composition, Michael Costello (director)
17-11
State Gazette act Appointment: Michael Costello (managing director)
Accounting effect3 facts ▸
  • Board meeting, 10-10-2011
  • Director appointment, Michael Costello (managing director)
  • Accounting effect, 10-10-2011
26-10
State Gazette act Resignation: Renaud Mazy (director and managing director)
6 facts ▸
  • General meeting, 15-09-2011
  • Director resignation, Renaud Mazy (director and managing director)
  • Board composition, Anja Verbeke (director)
  • Board composition, Emmanuel Foy (director)
  • Board composition, Philippe Lodomez (director)
  • Board composition, Mario Ricard (director)
20-09
State Gazette act Resignations & appointments
Power of attorney4 facts ▸
  • Board meeting, 01-08-2011
  • Power of attorney, Hendrik Deforce
  • Power of attorney, Jean-Michel Heusdens
  • Power of attorney, Philippe Lodomez
23-02
State Gazette act Resignation: Christian De Vos (director)
Appointments: Philippe Lodomez (director) and Mario Ricard (director) · Permanent representative: Philippe Lodomez · Mandate compensation12 facts ▸
  • General meeting, 16-12-2010
  • Director resignation, Christian De Vos (director)
  • Director appointment, Philippe Lodomez (director)
  • Mandate compensation, Philippe Lodomez
  • Director appointment, Mario Ricard (director)
  • Mandate compensation, Mario Ricard
  • Board composition, Renaud Mazy (director)
  • Board composition, Anja Verbeke (director)
  • Board composition, Emmanuel Foy (director)
  • Board composition, Philippe Lodomez (director)
  • Board composition, Mario Ricard (director)
  • Permanent representative, Philippe Lodomez
2010
16-11
State Gazette act Resignation: Mario Ricard (director)
Appointment: Emmanuel Foy (director)7 facts ▸
  • General meeting, 15-10-2010
  • Director resignation, Mario Ricard (director)
  • Director appointment, Emmanuel Foy (director)
  • Board composition, Christian De Vos (director)
  • Board composition, Renaud Mazy (director)
  • Board composition, Anja Verbeke (director)
  • Board composition, Emmanuel Foy (director)
02-09
State Gazette act Reappointment: SCCRL PricewaterhouseCoopers Reviseurs d'Entreprises (statutory auditor)
Permanent representative: Raynald Vermoesen3 facts ▸
  • General meeting, 17-06-2010
  • Auditor reappointment, SCCRL PricewaterhouseCoopers Reviseurs d'Entreprises
  • Permanent representative, Raynald Vermoesen (permanent representative)
19-05
State Gazette act Resignation: Pierre Destexhe (director)
Appointment: Anja Verbeke (director) · Permanent representative: Christian De Vos8 facts ▸
  • General meeting, 03-05-2010
  • Director resignation, Pierre Destexhe (director)
  • Director appointment, Anja Verbeke (director)
  • Board composition, Christian De Vos (director)
  • Board composition, Renaud Mazy (director)
  • Board composition, Mario Ricard (director)
  • Board composition, Anja Verbeke (director)
  • Permanent representative, Christian De Vos (administrateur de groupe a de baxter pension fund belgium)
19-05
State Gazette act Resignation: Anne Vissenackens (director)
Permanent representative: Mario Ricard7 facts ▸
  • General meeting, 12-03-2010
  • Director resignation, Anne Vissenackens (director)
  • Board composition, Pierre Destexhe (director)
  • Board composition, Christian De Vos (director)
  • Board composition, Renaud Mazy (director)
  • Board composition, Mario Ricard (director)
  • Permanent representative, Mario Ricard (permanent representative)
2008
27-08
State Gazette act Reappointments: Pierre Destexhe, Renaud Mazy and Christan De Vos
Resignations: Vinciane Verbiest (director) and Paul Van de Velde (director) · Appointment: Anne Vissenackens (director) · Permanent representative: Anne Vissenackens9 facts ▸
  • General meeting, 19-06-2008
  • Director reappointment, Pierre Destexhe (director)
  • Director reappointment, Renaud Mazy (director)
  • Director reappointment, Christan De Vos (director)
  • Director resignation, Vinciane Verbiest (director)
  • Director resignation, Paul Van de Velde (director)
  • Director appointment, Anne Vissenackens (director)
  • Permanent representative, Anne Vissenackens (permanent representative)
  • Mandate compensation, BAXTER
2005
22-09
State Gazette act Appointment: Dominique Cotteaux (managing director)
2 facts ▸
  • Board meeting, 19-08-2005
  • Director appointment, Dominique Cotteaux (managing director)
05-08
State Gazette act Appointment: Dominique Cotteaux (director)
Mandate compensation7 facts ▸
  • General meeting, 16-06-2005
  • Director appointment, Dominique Cotteaux (director)
  • Board composition, Pierre Destexhe (director)
  • Board composition, Christian De Vos (director)
  • Board composition, Vinciane Verbiest (director)
  • Board composition, Dominique Cotteaux (director)
  • Mandate compensation, Baxter
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
43 of 43 acts read

Directors · office · real estate

Directors
5 directors, 1 in day-to-day management, no change since 2025

Board 5

Frédéric Yannart
Director · since 01-01-2021
Current
Annelies Bryon
Director · since 15-07-2023
Current
Guy In 't Ven
Director · since 15-07-2023
Current
Serge Vandermotten
Director · since 15-07-2023
Current
Abdellah El Kacem
Director · since 28-03-2025
Current
4 not recently confirmed
Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.
Dominique Cotteaux
Director · since 16-06-2005
Not recently confirmed
Christan De Vos
Director · since 19-06-2008
Not recently confirmed
Achille Ghilotti
Director · since 01-10-2012
Not recently confirmed
Hermann Jacobs
Director · since 30-06-2014
Not recently confirmed

Day-to-day management 1

Annelies Bryon
Managing director · since 15-07-2023
Current
1 not recently confirmed
Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.
Dominique Cotteaux
Managing director · since 19-08-2005
Not recently confirmed

Statutory auditor 1

PwC Réviseurs d'Entreprises SRL
Auditor · since 17-06-2010 · perm. rep.: Romain Seffer
Current
Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ. See the function holders in the CBE →
Location & real-estate footprint
Registered office, Lessines · 2 establishment units since 1970
seat establishment All 2 establishment units on the map
Ground area
9.3 ha
Building footprint
4.0 ha
Volume, LiDAR
68,672 m³
Parcel 55023C0872/00Y000, Wallonia · tallest building 15.5 m. Linked by address, not a title deed.
2 establishment units
BAXTER
Boulevard René Branquart(L) 80, 7860 LessinesManufacture of basic metals
since 19702.105.442.804
Medical Products
Boulevard René Branquart(L) 80, 7860 LessinesManufacture of basic pharmaceutical products and pharmaceutical preparations
since 20122.215.045.973
1 parcel
Wallonia 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
55023C0872/00Y000 Wallonia 9.3 ha 1 · 4.0 ha 15.5 m
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Mandate history

32 people since 2005, 10 in office
Show
  • Board
  • Day-to-day management
  • Statutory auditor
  • Other function
  • not recently confirmed
  • began earlier
Mandates per person, with start and end dates
Name Functions and periods
Frédéric Yannart
  • Director, from 01-01-2021 to date
Annelies Bryon
  • Director, from 15-07-2023 to date
  • Managing director, from 15-07-2023 to date
Guy In 't Ven
  • Director, from 15-07-2023 to date
Serge Vandermotten
  • Director, from 15-07-2023 to date
Abdellah El Kacem
  • Director, from 28-03-2025 to date
PwC Réviseurs d'Entreprises SRL
  • Auditor, from 17-06-2010 to date
Dominique Cotteaux
  • Director, from 16-06-2005 not ended, last confirmed 05-08-2005
  • Managing director, from 19-08-2005 not ended, last confirmed 22-09-2005
Christan De Vos
  • Director, already before 19-06-2008 not ended, last confirmed 27-08-2008
Achille Ghilotti
  • Director, from 01-10-2012 not ended, last confirmed 04-12-2012
Hermann Jacobs
  • Director, already before 30-06-2014 not ended, last confirmed 04-03-2015
Lionel ROSOUX
  • Director, from 01-03-2024 to 28-03-2025
  • Managing director, from 01-03-2024 to 28-03-2025
Herman Jacobs
  • Director, from 01-05-2013 to 31-05-2024
Adriano Marques Antunes
  • Director, from 01-01-2022 to 15-02-2024
  • Managing director, from 15-07-2023 to 15-02-2024
Jacques Delbecq
  • Director, from 01-01-2021 to 15-07-2023
Bhevan Chandrasena
  • Director, from 15-03-2016 to 31-01-2022
Giuseppe Spatola
  • Director, from 01-07-2019 to 31-12-2020
Andrea BORRELL VILA
  • Director, from 01-07-2012 to 30-10-2019
Erich KOLLEGGER
  • Director, from 01-01-2014 to 31-12-2017
Philippe LODOMEZ
  • Director, from 01-01-2011 to 28-10-2015
Emmanuel FELIX
  • Director, from 01-05-2013 to 04-06-2015
Achille Ghillotti
  • Director, until 31-12-2013
Mario Ricard
  • Director, until 15-10-2010
  • Director, from 01-01-2011 to 01-05-2013
Emmanuel Foy
  • Director, from 15-10-2010 to 01-11-2012
Michael Costello
  • Director, from 10-10-2011 to 01-10-2012
  • Managing director, from 10-10-2011 ended, last mentioned 17-11-2011
Anja Verbeke
  • Director, from 03-05-2010 to 30-06-2012
Renaud MAZY
  • Director, already before 19-06-2008 to 15-09-2011
  • Director and managing director, until 15-09-2011
Raynald Vermoesen
  • Permanent representative, until 01-07-2011
Christian De Vos
  • Director, until 31-12-2010
Pierre Destexhe
  • Director, already before 19-06-2008 to 03-05-2010
Anne Vissenackens
  • Director, from 19-06-2008 to 01-04-2010
Van de Velde Paul
  • Director, until 30-05-2008
Vinciane Verbiest
  • Director, until 25-04-2008
See the board, name and seat on a given date →

Articles of association

Purpose
La société a pour objet de faire, pour son compte ou pour compte de tiers, la fabrication, la préparation, le conditionnement, le commerce et l'exploitation de tous produits…
Full purpose

La société a pour objet de faire, pour son compte ou pour compte de tiers, la fabrication, la préparation, le conditionnement, le commerce et l'exploitation de tous produits, spécialités, articles et accessoires destinés à l'usage pharmaceutique, thérapeutique, diététique, chirurgical, de tous instruments de chirurgie, de tous produits chimiques, de tous articles d'hygiène, de parfumerie et de droguerie, ainsi que toutes études, recherches et analyses y relatives.

according to the deed of 24-08-2021

Structure & network

Owners and holdings

4 holdings

Owners 0

The accounts to 31-12-2025 list no shareholders, and no other source names one.

Holdings 4

According to the 2025 annual accounts of BAXTER and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.

Connections & network

17 connected companies
Depth
AGORIA, Shared director AAGORIABAXALTA BELGIUM MANUFACTURING, 5 shared directors BBBAXALTA BELGIUMMANUFACTURINGBaxter R and D Europe, 2 shared directors BRBaxter R and DEuropeBaxter World Trade, 2 shared directors BWBaxter WorldTradeCENTRE HOSPITALIER UNIVERSITAIRE DINANT GODINNE SAINTE-ELISABETH-UCL-NAMUR, Shared director CHCENTREHOSPITALIER…Cliniques de l'Europe - Europa Ziekenhuizen, Shared director CDCliniques del'Europe…Cliniques universitaires Saint-Luc, Shared director CUCliniquesuniversitaires…CONTRIBUONS A UNE WALLONIE PICARDE DE QUALITÉ, Shared director CACONTRIBUONS AUNE WALLONIE…EPM ACADEMY, Shared director EAEPM ACADEMYFondation Saint - Luc, Shared director FSFondationSaint - LucForum Nucléaire Belge-Belgisch Nucleair Forum, Shared director FNForumNucléaire…Gezondheidsinstellingen Brussel Bruxelles Institutions de Santé, Shared director GBGezondheidsin…Brussel…GlaxoSmithKline Biologicals, Shared director GBGlaxoSmithKlineBiologicalsINSTITUT NATIONAL DES RADIOELEMENTS, Shared director ININSTITUTNATIONAL DES…BAXTER BAXTER0403.093.693
Shared directors
This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, scroll to zoom.
Linked via shared directors
AGORIA
Shared director
→
BAXALTA BELGIUM MANUFACTURING
Shared director
→
Baxter R and D Europe
Shared director
→
Baxter World Trade
Shared director
→
Show 13 more companies with a shared director
CENTRE HOSPITALIER UNIVERSITAIRE DINANT GODINNE SAINTE-ELISABETH-UCL-NAMUR
Shared director
→
Cliniques de l'Europe - Europa Ziekenhuizen
Shared director
→
Cliniques universitaires Saint-Luc
Shared director
→
CONTRIBUONS A UNE WALLONIE PICARDE DE QUALITÉ
Shared director
→
EPM ACADEMY
Shared director
→
Fondation Saint - Luc
Shared director
→
Forum Nucléaire Belge-Belgisch Nucleair Forum
Shared director
→
Gezondheidsinstellingen Brussel Bruxelles Institutions de Santé
Shared director
→
GlaxoSmithKline Biologicals
Shared director
→
INSTITUT NATIONAL DES RADIOELEMENTS
Shared director
→
LA CONFÉRENCE DES HÔPITAUX ACADÉMIQUES DE BELGIQUE
Shared director
→
MercurHosp
Shared director
→
SOPARTEC
Shared director
→

Ownership & control

1 board mandate
Board mandates of this companythis company sits on their board1
Baxter Pension Fund Belgium

Acquisitions and mergers

1 transaction
BE 0563.700.454partial demerger · State Gazette act of 06-07-2015 (4 acts) · effective 30-04-2015

Capital and shareholders

Shareholders according to the acts
Stated in the act act of 12-03-2015 ↗
  • Baxter Netherlands Holding B.V. 10,415 shares · 99,9712%
  • Baxter Sales and Distribution Corp. 3 shares · 0,0288%

The Belgian State Gazette names shareholders only when an act mentions them; the share register itself is not published.

Capital over the years
  1. 24-08-2021 Capital stated in the act · 7,122,417 EUR · 10,418 shares
  2. 06-07-2015 Capital reduction of 15,614,853 EUR · to 7,122,417 EUR
  3. 12-03-2015 Capital reduction of 15,614,853 EUR · to 7,122,417 EUR · “apport des Activités Baxalta”

Similar companies · same sector, comparable size

PHYSIOL
BE 0428.242.033
Liège · Eq €78.4m
Pfizer
BE 0401.994.823
Elsene · Eq €90.4m
ODYSSEA PHARMA
BE 0892.121.272
Grâce-Hollogne · Eq €76.4m
Novo Nordisk Production Belgium SA
BE 0465.935.738
Brussel · Eq €74.2m
ROCHE
BE 0403.088.151
Anderlecht · Eq €64.5m
Of 148 companies in sector 21201 we hold annual accounts for 118. 35 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification
Legal formPublic limited company
Founded01-01-1968
Fiscal year end31-12
Activities, NACEBEL 2025
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
E-invoicing
Reachable via Peppol
Peppol ID 0208:0403093693
Registered 30-01-2026

If you follow this company, Checked tells you the day it leaves the Peppol register.

Register as of 29 September 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.

We would like to set cookies. That happens only with your consent. What we measure